Literature DB >> 18703633

The effects of apelin on the electrical activity of hypothalamic magnocellular vasopressin and oxytocin neurons and somatodendritic Peptide release.

Vicky A Tobin1, Philip M Bull, Sathya Arunachalam, Anne-Marie O'Carroll, Yoichi Ueta, Mike Ludwig.   

Abstract

Apelin, a novel peptide originally isolated from bovine stomach tissue extracts, is widely but selectively distributed throughout the nervous system. Vasopressin and oxytocin are synthesized in the magnocellular neurons of the hypothalamic supraoptic nucleus (SON) and paraventricular nucleus, which are apelin-rich regions in the central nervous system. We made extracellular electrophysiological recordings from the transpharyngeally exposed SON of urethane-anaesthetized rats to assess the role of apelin in the control of the firing activity of identified magnocellular vasopressin and oxytocin neurons in vivo. Apelin-13 administration onto SON neurons via microdialysis revealed cell-specific responses; apelin-13 increased the firing rates of vasopressin cells but had no effect on the firing rate of oxytocin neurons. A direct excitatory effect of apelin-13 on vasopressin cell activity is also supported by our in vitro studies showing depolarization of membrane potential and increase in action potential firing. To assess the effects of apelin-13 on somatodendritic peptide release, we used in vitro release studies from SON explants in combination with highly sensitive and specific RIA. Apelin-13 decreases basal (by 78%; P < 0.05; n = 6) and potassium-stimulated (by 57%; P < 0.05; n = 6) vasopressin release but had no effect on somatodendritic oxytocin release. Taken together, our data suggest a local autocrine feedback action of apelin on magnocellular vasopressin neurons. Furthermore, these data show a marked dissociation between axonal and dendritic vasopressin release with a decrease in somatodendritic release but an increase in electrical activity at the cell bodies, indicating that release from these two compartments can be regulated wholly independently.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18703633      PMCID: PMC2670455          DOI: 10.1210/en.2008-0178

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  58 in total

Review 1.  Emerging roles of apelin in biology and medicine.

Authors:  Matthias J Kleinz; Anthony P Davenport
Journal:  Pharmacol Ther       Date:  2005-08       Impact factor: 12.310

Review 2.  Dendritic release of vasopressin and oxytocin.

Authors:  M Ludwig
Journal:  J Neuroendocrinol       Date:  1998-12       Impact factor: 3.627

3.  Characterization of apelin, the ligand for the APJ receptor.

Authors:  D K Lee; R Cheng; T Nguyen; T Fan; A P Kariyawasam; Y Liu; D H Osmond; S R George; B F O'Dowd
Journal:  J Neurochem       Date:  2000-01       Impact factor: 5.372

4.  Exaggerated response of arginine vasopressin-enhanced green fluorescent protein fusion gene to salt loading without disturbance of body fluid homeostasis in rats.

Authors:  T Fujio; H Fujihara; M Shibata; S Yamada; T Onaka; K Tanaka; H Morita; G Dayanithi; M Kawata; D Murphy; Y Ueta
Journal:  J Neuroendocrinol       Date:  2006-10       Impact factor: 3.627

5.  Distribution of mRNA encoding B78/apj, the rat homologue of the human APJ receptor, and its endogenous ligand apelin in brain and peripheral tissues.

Authors:  A M O'Carroll; T L Selby; M Palkovits; S J Lolait
Journal:  Biochim Biophys Acta       Date:  2000-06-21

6.  Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice.

Authors:  Jiu-Chang Zhong; Xi-Yong Yu; Yu Huang; Lai-Ming Yung; Chi-Wai Lau; Shu-Guang Lin
Journal:  Cardiovasc Res       Date:  2007-02-12       Impact factor: 10.787

7.  Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin.

Authors:  Andrew D Medhurst; Carol A Jennings; Melanie J Robbins; Robert P Davis; Catherine Ellis; Kim Y Winborn; Kenneth W M Lawrie; Guillaume Hervieu; Graham Riley; Jane E Bolaky; Nicole C Herrity; Paul Murdock; John G Darker
Journal:  J Neurochem       Date:  2003-03       Impact factor: 5.372

8.  Modification of the terminal residue of apelin-13 antagonizes its hypotensive action.

Authors:  Dennis K Lee; Victor R Saldivia; Tuan Nguyen; Regina Cheng; Susan R George; Brian F O'Dowd
Journal:  Endocrinology       Date:  2004-10-14       Impact factor: 4.736

Review 9.  A putative role for apelin in the etiology of obesity.

Authors:  Srujana Rayalam; Mary Anne Della-Fera; Paul A Krieg; Christopher M Cox; Allan Robins; Clifton A Baile
Journal:  Biochem Biophys Res Commun       Date:  2008-02-12       Impact factor: 3.575

10.  Regulation of rat APJ receptor messenger ribonucleic acid expression in magnocellular neurones of the paraventricular and supraopric nuclei by osmotic stimuli.

Authors:  A-M O'Carroll; S J Lolait
Journal:  J Neuroendocrinol       Date:  2003-07       Impact factor: 3.627

View more
  19 in total

1.  Pressor effect of apelin-13 in the rostral ventrolateral medulla: role of NAD(P)H oxidase-derived superoxide.

Authors:  Fanrong Yao; Amit Modgil; Qi Zhang; Ajeeth Pingili; Neha Singh; Stephen T O'Rourke; Chengwen Sun
Journal:  J Pharmacol Exp Ther       Date:  2010-11-03       Impact factor: 4.030

Review 2.  Novel transmitters in brain stem vagal neurocircuitry: new players on the pitch.

Authors:  Mehmet Bülbül; R Alberto Travagli
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-03-29       Impact factor: 4.052

3.  Apelin acts in the subfornical organ to influence neuronal excitability and cardiovascular function.

Authors:  Li Dai; Pauline M Smith; Markus Kuksis; Alastair V Ferguson
Journal:  J Physiol       Date:  2013-04-29       Impact factor: 5.182

4.  Apelin gene transfer into the rostral ventrolateral medulla induces chronic blood pressure elevation in normotensive rats.

Authors:  Qi Zhang; Fanrong Yao; Mohan K Raizada; Stephen T O'Rourke; Chengwen Sun
Journal:  Circ Res       Date:  2009-05-14       Impact factor: 17.367

5.  An intrinsic vasopressin system in the olfactory bulb is involved in social recognition.

Authors:  Vicky A Tobin; Hirofumi Hashimoto; Douglas W Wacker; Yuki Takayanagi; Kristina Langnaese; Celine Caquineau; Julia Noack; Rainer Landgraf; Tatsushi Onaka; Gareth Leng; Simone L Meddle; Mario Engelmann; Mike Ludwig
Journal:  Nature       Date:  2010-02-24       Impact factor: 49.962

Review 6.  Physiological regulation of magnocellular neurosecretory cell activity: integration of intrinsic, local and afferent mechanisms.

Authors:  C H Brown; J S Bains; M Ludwig; J E Stern
Journal:  J Neuroendocrinol       Date:  2013-08       Impact factor: 3.627

Review 7.  G protein-coupled receptors in the hypothalamic paraventricular and supraoptic nuclei--serpentine gateways to neuroendocrine homeostasis.

Authors:  Georgina G J Hazell; Charles C Hindmarch; George R Pope; James A Roper; Stafford L Lightman; David Murphy; Anne-Marie O'Carroll; Stephen J Lolait
Journal:  Front Neuroendocrinol       Date:  2011-07-23       Impact factor: 8.606

8.  Central and peripheral apelin receptor distribution in the mouse: species differences with rat.

Authors:  George R Pope; Emma M Roberts; Stephen J Lolait; Anne-Marie O'Carroll
Journal:  Peptides       Date:  2011-12-16       Impact factor: 3.750

9.  Abnormal fluid homeostasis in apelin receptor knockout mice.

Authors:  Emma M Roberts; Michael J F Newson; George R Pope; Rainer Landgraf; Stephen J Lolait; Anne-Marie O'Carroll
Journal:  J Endocrinol       Date:  2009-07-03       Impact factor: 4.286

Review 10.  International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand.

Authors:  Cai Read; Duuamene Nyimanu; Thomas L Williams; David J Huggins; Petra Sulentic; Robyn G C Macrae; Peiran Yang; Robert C Glen; Janet J Maguire; Anthony P Davenport
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.